<table>
<thead>
<tr>
<th></th>
<th>Overall (n=213)</th>
<th>CPVI (n=106)</th>
<th>Line (n=107)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>58.6 ± 10.7</td>
<td>58.7 ± 11.0</td>
<td>58.5 ± 10.6</td>
<td>0.866</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>177 (83.1)</td>
<td>85 (80.2)</td>
<td>92 (86)</td>
<td>0.259</td>
</tr>
<tr>
<td>AF duration</td>
<td>39.3 ± 39.9</td>
<td>32.8 ± 32.1</td>
<td>45.6 ± 45.5</td>
<td>0.03</td>
</tr>
<tr>
<td>Longstanding PeAF</td>
<td>139 (65.3)</td>
<td>65 (61.3)</td>
<td>74 (69.2)</td>
<td>0.23</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>49 (23)</td>
<td>24 (22.6)</td>
<td>25 (23.4)</td>
<td>0.9</td>
</tr>
<tr>
<td>Hypertension</td>
<td>100 (46.9)</td>
<td>55 (51.9)</td>
<td>45 (42.1)</td>
<td>0.151</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>31 (14.6)</td>
<td>18 (17)</td>
<td>13 (12.1)</td>
<td>0.317</td>
</tr>
<tr>
<td>Stroke</td>
<td>23 (10.8)</td>
<td>13 (12.3)</td>
<td>10 (9.3)</td>
<td>0.493</td>
</tr>
<tr>
<td>TIA</td>
<td>3 (1.4)</td>
<td>1 (0.9)</td>
<td>2 (1.9)</td>
<td>1</td>
</tr>
<tr>
<td>Vascular disease</td>
<td>13 (6.1)</td>
<td>6 (5.7)</td>
<td>7 (6.6)</td>
<td>0.775</td>
</tr>
<tr>
<td>CHA2DS2-VASc score</td>
<td>1.7 ± 1.4</td>
<td>1.9 ± 1.5</td>
<td>1.5 ± 1.3</td>
<td>0.08</td>
</tr>
<tr>
<td>Echocardiographic parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA dimension, mm</td>
<td>44.7 ± 6.0</td>
<td>44.5 ± 6.6</td>
<td>44.9 ± 5.4</td>
<td>0.642</td>
</tr>
<tr>
<td>LA volume index, ml/m²</td>
<td>43.5 ± 12.9</td>
<td>43.1 ± 11.4</td>
<td>43.8 ± 14.2</td>
<td>0.71</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
<td>58.8 ± 9.4</td>
<td>58.9 ± 8.7</td>
<td>58.8 ± 10.2</td>
<td>0.931</td>
</tr>
<tr>
<td>E/Em</td>
<td>10.0 ± 4.3</td>
<td>10.5 ± 4.9</td>
<td>9.6 ± 3.5</td>
<td>0.128</td>
</tr>
<tr>
<td>LVEDD, mm</td>
<td>50.3 ± 5.3</td>
<td>50.4 ± 5.0</td>
<td>50.2 ± 5.7</td>
<td>0.818</td>
</tr>
<tr>
<td></td>
<td>Overall (n=213)</td>
<td>CPVI (n=106)</td>
<td>Line (n=107)</td>
<td>p-value</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------</td>
</tr>
<tr>
<td>Procedure time, min</td>
<td>218.3 ± 74.7</td>
<td>206.4 ± 77.4</td>
<td>230.1 ± 70.4</td>
<td>0.02</td>
</tr>
<tr>
<td>Ablation time, sec</td>
<td>4778.7 ± 2227.8</td>
<td>4211.3 ± 1920.2</td>
<td>5340.8 ± 2373.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fluoroscopy time, min</td>
<td>36.4 ± 17.3</td>
<td>35.0 ± 18.1</td>
<td>37.8 ± 16.5</td>
<td>0.24</td>
</tr>
<tr>
<td>†Complications</td>
<td>12 (5.6)</td>
<td>7 (6.6)</td>
<td>5 (4.7)</td>
<td>0.541</td>
</tr>
<tr>
<td>Major Complications</td>
<td>6 (2.8)</td>
<td>5 (4.7)</td>
<td>1 (0.9)</td>
<td>0.119</td>
</tr>
<tr>
<td>Tamponade</td>
<td>4 (1.9)</td>
<td>4 (3.8)</td>
<td>0</td>
<td>0.090</td>
</tr>
<tr>
<td>SSS</td>
<td>2 (0.9)</td>
<td>0</td>
<td>2 (1.9)</td>
<td>0.498</td>
</tr>
<tr>
<td>AE fistula</td>
<td>2 (0.9)</td>
<td>1 (1)</td>
<td>1 (0.9)</td>
<td>0.748</td>
</tr>
</tbody>
</table>

† Complications: pericarditis, pseudoaneurysm, pericardial effusion, Tamponade, SSS, AE fistula
<table>
<thead>
<tr>
<th></th>
<th>Overall (n=213)</th>
<th>CPVI (n=106)</th>
<th>Line (n=107)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Post-ABL medication</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARB, n (%)</td>
<td>72 (33.8)</td>
<td>42 (39.6)</td>
<td>30 (28.0)</td>
<td>0.074</td>
</tr>
<tr>
<td>Beta blocker, n (%)</td>
<td>84 (39.4)</td>
<td>46 (43.4)</td>
<td>38 (35.5)</td>
<td>0.341</td>
</tr>
<tr>
<td>Statin, n (%)</td>
<td>71 (33.3)</td>
<td>37 (34.9)</td>
<td>34 (31.8)</td>
<td>0.562</td>
</tr>
<tr>
<td>AAD, n (%)</td>
<td>94 (44.1)</td>
<td>55 (51.9)</td>
<td>39 (36.4)</td>
<td>0.059</td>
</tr>
<tr>
<td><strong>Follow-up, months</strong></td>
<td>16.1 ± 8.9</td>
<td>16.3 ± 8.8</td>
<td>15.9 ± 9.1</td>
<td>0.724</td>
</tr>
<tr>
<td><strong>Early recurrence, n (%)</strong></td>
<td>92 (43.2)</td>
<td>44 (41.5)</td>
<td>48 (44.9)</td>
<td>0.622</td>
</tr>
<tr>
<td>Recurrence type AF, n (%)</td>
<td>56 (60.9)</td>
<td>29 (66.0)</td>
<td>27 (56.3)</td>
<td>0.232</td>
</tr>
<tr>
<td>Recurrence type AT, n (%)</td>
<td>24 (26.1)</td>
<td>8 (18.2)</td>
<td>16 (33.3)</td>
<td>0.232</td>
</tr>
<tr>
<td><strong>Clinical recurrence, n (%)</strong></td>
<td>48 (22.5)</td>
<td>23 (21.7)</td>
<td>25 (23.4)</td>
<td>0.771</td>
</tr>
<tr>
<td>Recurrence type AF, n (%)</td>
<td>39 (84.4)</td>
<td>19 (90.5)</td>
<td>20 (80)</td>
<td>0.428</td>
</tr>
<tr>
<td>Recurrence type AT, n (%)</td>
<td>7 (15.2)</td>
<td>2 (9.5)</td>
<td>5 (20)</td>
<td>0.428</td>
</tr>
<tr>
<td>AAD at recurrence, n (%)</td>
<td>32 (66.7)</td>
<td>15 (65.2)</td>
<td>17 (68.0)</td>
<td>0.723</td>
</tr>
<tr>
<td>Cardioversion, n (%)</td>
<td>38 (17.8)</td>
<td>16 (15.1)</td>
<td>22 (20.6)</td>
<td>0.297</td>
</tr>
<tr>
<td><strong>Final rhythm type AF or AT n(%)</strong></td>
<td>30 (14.1)</td>
<td>14 (13.2)</td>
<td>16 (15)</td>
<td>0.714</td>
</tr>
<tr>
<td><strong>Final rhythm type SR, n(%)</strong></td>
<td>183 (85.9)</td>
<td>92 (86.8)</td>
<td>91 (85)</td>
<td>0.714</td>
</tr>
<tr>
<td><strong>Continued use of AAD</strong></td>
<td>99 (46.5)</td>
<td>55 (51.9)</td>
<td>44 (41.1)</td>
<td>0.115</td>
</tr>
<tr>
<td><strong>Maintenance of NSR without AAD</strong></td>
<td>103 (48.4)</td>
<td>47 (44.3)</td>
<td>56 (52.3)</td>
<td>0.243</td>
</tr>
</tbody>
</table>
Overall

Log-rank Test
P=0.272

CPVI
Line
Follow up Months
Freedom From AF recurrence, (%)
CPVI 82 74 48 27 11 0
Line 83 70 46 25 5 0

AAD Free

Log-rank Test
P=0.251

CPVI
Line
Follow up Months
Freedom From AF recurrence, (%)
CPVI 39 37 31 17 6 0
Line 47 40 31 18 4 0